Results 101 to 110 of about 275,584 (397)

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. [PDF]

open access: yes, 2018
Regulatory T cells (Tregs) are critical for maintaining immune homeostasis, but their presence in tumor tissues impairs anti-tumor immunity and portends poor prognoses in cancer patients.
Abnousian, Arbi   +14 more
core   +2 more sources

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo   +9 more
wiley   +1 more source

Depletion of CD25+ cells during acute toxoplasmosis does not significantly increase mortality in Swiss OF1 mice

open access: yesMemorias do Instituto Oswaldo Cruz, 2012
The interleukin (IL)-2R alpha chain (CD25) is expressed on regulatory T cells (Treg), which constitute more than 85% of the CD25+ T cell population in a naïve mouse.
Haroon Akbar   +4 more
doaj   +1 more source

DCAF1 regulates Treg senescence via the ROS axis during immunological ageing.

open access: yesJournal of Clinical Investigation, 2020
As a hallmark of immunological ageing, the low-grade, chronic inflammation with accumulation of effector-memory T cells contributes to the increased susceptibility of many ageing-related diseases. While the proinflammatory state of aged T cells indicates
Zengli Guo   +11 more
semanticscholar   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

MALT1 proteolytic activity suppresses autoimmunity in a T cell intrinsic manner [PDF]

open access: yes, 2019
MALT1 is a central signaling component in innate and adaptive immunity by regulating NF-kappa B and other key signaling pathways in different cell types. Activities of MALT1 are mediated by its scaffold and protease functions.
Baens, Mathijs   +7 more
core   +2 more sources

Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models

open access: yesAdvanced Functional Materials, EarlyView.
Structure–activity relationship (SAR) optimization of bio‐reducible ionizable lipids enables the development of highly effective lipid nanoparticle (LNP) mRNA vaccines. Lead LNPs show superior tolerability and antibody responses in rodents and primates, outperforming approved COVID‐19 vaccine lipids.
Ruben De Coen   +30 more
wiley   +1 more source

Controversies concerning thymus-derived regulatory T cells: fundamental issues and a new perspective [PDF]

open access: yes, 2015
Thymus-derived regulatory T cells (Tregs) are considered to be a distinct T-cell lineage that is genetically programmed and specialised for immunosuppression.
Ono, M, Tanaka, RJ
core   +1 more source

TLRs toll for Tregs [PDF]

open access: yesJournal of Leukocyte Biology, 2019
Abstract Discussion on TLR3 triggering in CD4 T cells induces IFN beta and IL10-producing iTregs that suppress food allergy.
openaire   +3 more sources

Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME

open access: yesAdvanced Functional Materials, EarlyView.
A quinone methide‐gated, self‐immolative, H2O2‐responsive nano‐photosensitizer (Pyz/PS) is developed for targeted immuno‐photodynamic therapy. Pyz/PS selectively activates within tumor microenvironments, restores photosensitizer activity, generates ROS, and depletes intracellular GSH, enhancing oxidative stress.
Jing Li   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy